Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BN83495

Known as: Steroid Sulfatase Inhibitor BN 83495 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
2011
2011
Structure–activity relationship studies were conducted on Irosustat (STX64, BN83495), the first steroid sulfatase (STS) inhibitor… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Review
2011
Review
2011
Hydrolysis of biologically inactive steroid sulfates to unconjugated steroids by steroid sulfatase (STS) is strongly implicated… Expand
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
Review
2011
Review
2011
Endocrine therapy is a key modality in the management of breast cancer, with current options for postmenopausal women including… Expand
Is this relevant?
Review
2011
Review
2011
Steroid sulfatase plays a pivotal role in regulating the formation of biologically active steroids from inactive steroid sulfates… Expand
  • figure 1
Is this relevant?
2009
2009
Background: BN83495/STX64 is an irreversible steroid sulfatase (STS) inhibitor blocking the hydrolysis of sulfated estrone E1S… Expand
Is this relevant?
2008
2008
The past few years have seen an increase in the reported incidence of endometrial carcinoma, one of the most frequently diagnosed… Expand
Is this relevant?
2008
2008
Steroid sulphatase (STS) inhibitors have been developed primarily for the treatment of hormone-dependent breast cancer, but may… Expand
Is this relevant?
Review
2007
Review
2007
Inhibitors of steroid sulfatase are being developed as a novel therapy for hormone-dependent breast cancer in postmenopausal… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2007
2007
SY25-01 Breast cancer remains a major cause of death in women in most Western countries. While estrogens have an important role… Expand
Is this relevant?